AIMS/HYPOTHESIS: The newly identified liver- and fat-derived hormone, betatrophin, has recently been linked to insulin resistance and pancreatic beta cell growth in mice. These preclinical findings have suggested betatrophin as a potential candidate for novel glucose-lowering treatment concepts involving beta cell regeneration. However, the role of betatrophin in human insulin resistance and type 2 diabetes is currently unknown. Hence, the aim of this study was to investigate circulating betatrophin concentrations in two distinct cohorts with insulin resistance. METHODS: Betatrophin concentrations were analysed in (1) age- and sex-matched lean (n = 20) and morbidly obese individuals (n = 19), and (2) age-, sex- and BMI-matched non-diabetic (n = 19) and type 2 diabetic individuals (n = 18). RESULTS: Betatrophin concentrations did not differ between lean and morbidly obese or between non-diabetic and type 2 diabetic participants. No association was found with variables of beta cell function and glucose homeostasis. However, betatrophin did correlate significantly with plasma atherogenic lipids including total cholesterol, LDL-cholesterol and apolipoprotein B in morbidly obese and type 2 diabetic patients but not in controls. Insulin-resistant individuals with hypercholesterolaemia (≥5.2 mmol/l) had significantly higher betatrophin concentrations than those with normal cholesterol (<5.2 mmol/l). CONCLUSIONS/ INTERPRETATION: Betatrophin is a recently identified hormone, the circulating concentrations of which are unaltered in human insulin resistance but correlate significantly with atherogenic lipid profiles in high-risk cohorts with morbid obesity or type 2 diabetes. Betatrophin could therefore be a novel pathomechanistic player in dysfunctional lipid metabolism associated with high cardiovascular risk.
AIMS/HYPOTHESIS: The newly identified liver- and fat-derived hormone, betatrophin, has recently been linked to insulin resistance and pancreatic beta cell growth in mice. These preclinical findings have suggested betatrophin as a potential candidate for novel glucose-lowering treatment concepts involving beta cell regeneration. However, the role of betatrophin in humaninsulin resistance and type 2 diabetes is currently unknown. Hence, the aim of this study was to investigate circulating betatrophin concentrations in two distinct cohorts with insulin resistance. METHODS:Betatrophin concentrations were analysed in (1) age- and sex-matched lean (n = 20) and morbidly obese individuals (n = 19), and (2) age-, sex- and BMI-matched non-diabetic (n = 19) and type 2 diabetic individuals (n = 18). RESULTS:Betatrophin concentrations did not differ between lean and morbidly obese or between non-diabetic and type 2 diabeticparticipants. No association was found with variables of beta cell function and glucose homeostasis. However, betatrophin did correlate significantly with plasma atherogenic lipids including total cholesterol, LDL-cholesterol and apolipoprotein B in morbidly obese and type 2 diabeticpatients but not in controls. Insulin-resistant individuals with hypercholesterolaemia (≥5.2 mmol/l) had significantly higher betatrophin concentrations than those with normal cholesterol (<5.2 mmol/l). CONCLUSIONS/ INTERPRETATION:Betatrophin is a recently identified hormone, the circulating concentrations of which are unaltered in humaninsulin resistance but correlate significantly with atherogenic lipid profiles in high-risk cohorts with morbid obesity or type 2 diabetes. Betatrophin could therefore be a novel pathomechanistic player in dysfunctionallipid metabolism associated with high cardiovascular risk.
Authors: Anja Köster; Y Bernice Chao; Marian Mosior; Amy Ford; Patricia A Gonzalez-DeWhitt; John E Hale; Deshan Li; Yubin Qiu; Christopher C Fraser; Derek D Yang; Josef G Heuer; S Richard Jaskunas; Patrick Eacho Journal: Endocrinology Date: 2005-08-04 Impact factor: 4.736
Authors: Kiran Musunuru; James P Pirruccello; Ron Do; Gina M Peloso; Candace Guiducci; Carrie Sougnez; Kiran V Garimella; Sheila Fisher; Justin Abreu; Andrew J Barry; Tim Fennell; Eric Banks; Lauren Ambrogio; Kristian Cibulskis; Andrew Kernytsky; Elena Gonzalez; Nicholas Rudzicz; James C Engert; Mark A DePristo; Mark J Daly; Jonathan C Cohen; Helen H Hobbs; David Altshuler; Gustav Schonfeld; Stacey B Gabriel; Pin Yue; Sekar Kathiresan Journal: N Engl J Med Date: 2010-10-13 Impact factor: 91.245
Authors: Yan Wang; Fabiana Quagliarini; Viktoria Gusarova; Jesper Gromada; David M Valenzuela; Jonathan C Cohen; Helen H Hobbs Journal: Proc Natl Acad Sci U S A Date: 2013-09-16 Impact factor: 11.205
Authors: Fabiana Quagliarini; Yan Wang; Julia Kozlitina; Nick V Grishin; Rhonda Hyde; Eric Boerwinkle; David M Valenzuela; Andrew J Murphy; Jonathan C Cohen; Helen H Hobbs Journal: Proc Natl Acad Sci U S A Date: 2012-11-12 Impact factor: 11.205
Authors: S Kahraman; A E Altinova; M M Yalcin; O Gulbahar; B Arslan; M Akturk; N Cakir; F B Toruner Journal: J Endocrinol Invest Date: 2018-01-23 Impact factor: 4.256
Authors: Viktoria Gusarova; Corey A Alexa; Erqian Na; Panayiotis E Stevis; Yurong Xin; Susan Bonner-Weir; Jonathan C Cohen; Helen H Hobbs; Andrew J Murphy; George D Yancopoulos; Jesper Gromada Journal: Cell Date: 2014-10-23 Impact factor: 41.582
Authors: Robert L Hanson; Fatjon Leti; Darwin Tsinajinnie; Sayuko Kobes; Sobha Puppala; Joanne E Curran; Laura Almasy; Donna M Lehman; John Blangero; Ravindranath Duggirala; Johanna K DiStefano Journal: Mol Genet Metab Date: 2016-04-19 Impact factor: 4.797
Authors: A B Crujeiras; M A Zulet; I Abete; M Amil; M C Carreira; J A Martínez; F F Casanueva Journal: Int J Obes (Lond) Date: 2015-10-07 Impact factor: 5.095